2025年7月15日14时56分（格林尼治时间）讯——专业财经平台最新评级数据显示，瑞银集团日前发布研报，维持对生物制药企业辛达克斯制药（NASDAQ: SNDX）的买入评级。此次评级延续了该机构对这家专注于肿瘤创新疗法研发企业的积极展望，显示其核心产品管线进展持续获得资本市场认可。
尽管当前生物科技板块波动加剧，分析师仍看好辛达克斯制药在白血病治疗领域的突破性疗法研发进度。其主打候选药物revumenib的临床数据表现，被视作支撑当前评级的关键因素。值得注意的是，本次评级维持发生在公司即将公布关键性三期临床试验数据的重要窗口期前，反映出机构投资者对实验结果的审慎乐观预期。
（完）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.